Research Articles - QUALIblood

Marie Didembourg, Sara Reda, Johannes Oldenburg, Heiko Rühl, Jonathan Douxfils, Laure Morimont

Hemostatic imbalance induced by tamoxifen in estrogen receptor-positive breast cancer patients: An observational study

Int J Lab Hematol . 2024 Jan 31.

Douxfils, J. et al.

Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.

Clinical chemistry and laboratory medicine : CCLM / FESCC 58, 294-305 (2020).

Foidart, J. M. et al.

The Benefits of Estetrol Addition to Drospirenone for Contraception.

AJOG Global Reports (2023).

Evrard, J., Maloteau, V., Dogne, J. M. & Douxfils, J.

Simultaneous assessment of DOACs effect on clot formation and fibrinolysis with the FibWave.

International journal of laboratory hematology 44, e79-e83 (2022).

Douxfils, J., Beaudart, C. & Dogne, J.-M.

Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. The Lancet (2023). https://doi.org:10.1016/S0140-6736(23)01634-3

The Lancet (2023).

Gerard, C. et al.

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.

Expert Rev Clin Pharmacol 15, 121-137 (2022).

Morimont, L., Bouvy, C., Delvigne, A. S., Dogne, J. M. & Douxfils, J. https://doi.org:10.1111/jth.14745

Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance.

Journal of thrombosis and haemostasis : JTH 18, 895-904 (2020).

Douxfils, J., Morimont, L. & Bouvy, C.

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.

Seminars in thrombosis and hemostasis 46, 872-886 (2020).

Morimont, L. et al.

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone.

J Clin Endocrinol Metab 108, 135-143 (2022).

Morimont, L., Dogne, J. M. & Douxfils, J. https://doi.org:10.1016/j.thromres.2020.08.006

Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled “Estrogen and thrombosis: A bench to bedside review” (Thrombosis Research 192 (2020) 40-51).

Thrombosis research 193, 221-223 (2020).

Morimont, L. et al.

Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance.

Seminars in thrombosis and hemostasis (2022).

Morimont, L. et al.

Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay.

Res Pract Thromb Haemost 5, e12612 (2021).

Douxfils, J. et al.

Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women.

Climacteric 26, 55-63 (2023).

Morimont, L.

Hormone-induced coagulopathy – Evaluation of the prothrombotic state using a global coagulation assay

PhD in Biomedical and Pharmaceutical Sciencesæ thesis, University of Namur, (2023).

Morimont, L., Creinin, M. D., Gaspard, U., Foidart, J. M. & Douxfils, J.

Hormonal therapies and venous thrombosis: Estrogen matters!

Res Pract Thromb Haemost 7, 100021 (2023).

Douxfils, J. et al.

Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.

Contraception 102, 396-402 (2020).

Pouplard, M. et al.

Évaluation et prise en charge du risque thrombotique chez les patients hospitalisés atteints de Covid-19.

Hémato-Onco 14, 38-43 (2020).

Douxfils, J., Bouvy, C. & Morimont, L.

Evaluation of Activated Protein C Resistance Using Thrombin Generation Test.

Methods Mol Biol 2663, 211-224 (2023).

Douxfils, J., Morimont, L., Gaspard, U., Utian, W. H. & Foidart, J. M.

Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation.

Thrombosis research (2022).

Foidart, J. M. et al.

Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study.

Journal of Clinical Medicine 12, 3928 (2023).

Douxfils, J. et al.

Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC).

Maturitas 152, 69 (2021).

Bayart, J. L. et al.

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.

Microorganisms 9, 1340 (2021).

Morimont, L., Gaspard, U., Foidart, J. M., Dogné, J.-M. & Douxfils,

Contraceptifs oraux combinés et thrombo-embolie veineuse: quels sont vriament les risques?

J. in Medi-Sphere Vol. 701 39-48 (2022).

Morimont, L., Haguet, H., Dogne, J. M., Gaspard, U. & Douxfils, J.

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Front Endocrinol (Lausanne) 12, 769187 (2021).

Reda, S., Morimont, L., Douxfils, J. & Ruhl, H.

Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?

Hamostaseologie 40, 364-378 (2020).

Morimont, L. et al.

Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system.

Res Pract Thromb Haemost 6, e12684 (2022).

Gemzell-Danielsson, K. et al.

A novel estetrol-containing combined oral contraceptive: European expert panel review.

Eur J Contracept Reprod Health Care 27, 373-383 (2022).